Gastric Cancer

Key Points

• Gastric cancer commonly develops slowly and may remain clinically silent until late-stage progression.
• High-risk patterns include H. pylori infection, obesity, high-salt or charred-food intake, heavy alcohol use, and smoking.
• U.S. burden differences are noted with higher incidence in Hispanic Americans, Black Americans, and American Indians.
• Most cancers arise from mucus-producing gastric-lining cells and are classified as intestinal or diffuse adenocarcinoma patterns.
• Common advanced-presentation cues include weight loss, dysphagia, persistent abdominal pain, anorexia, nausea, hematemesis, early satiety, and indigestion.
• Nursing priorities are risk recognition, timely escalation for diagnostic workup, and coordination of multidisciplinary support.

Pathophysiology

Most gastric cancers begin in mucosa-lined glandular cells and are adenocarcinomas. Tumor biology and treatment planning vary by subtype.

Classification

• Intestinal adenocarcinoma pattern: More clustered cellular architecture and more likely mutation-associated targeted-therapy responsiveness.
• Diffuse adenocarcinoma pattern: More scattered cellular growth pattern and less conspicuous surface involvement.

Nursing Assessment

NCLEX Focus

Prioritize high-risk history clusters and do not down-triage persistent upper-GI symptom change in high-risk patients.

• Assess risk profile, including H. pylori history, smoking/alcohol exposure, obesity, and high-salt or charred-food dietary patterns.
• Recognize that early disease may be minimally symptomatic and symptom onset may reflect advanced progression.
• Assess for progressive symptom burden, including weight loss, dysphagia, persistent abdominal pain, anorexia, nausea, hematemesis, early satiety, and persistent indigestion.
• Monitor for concurrent upper-GI alarm cues (for example recurrent vomiting, progressive dysphagia/odynophagia, GI bleeding, or unexplained weight loss) and escalate promptly.
• Review family history and prior gastric-disease history when stratifying concern.

Diagnostics

• Upper endoscopy with biopsy: Most common diagnostic pathway to confirm gastric malignancy.
• Adjunct luminal imaging: Barium swallow may be used in selected scenarios.
• Metastasis and staging support: Abdominal CT, x-ray, endoscopic ultrasound, and serum studies are used to evaluate spread and treatment planning.
• Oncologic characterization: Histologic subtype (intestinal vs diffuse) informs staging and treatment-pathway planning once tissue diagnosis is established.

Nursing Interventions

• Escalate high-risk symptom profiles early, especially when symptoms persist despite routine reflux/ulcer treatment.
• Reinforce risk-reduction education (smoking and alcohol cessation, dietary modification, and H. pylori evaluation/treatment adherence).
• Support coordinated referral pathways across gastroenterology, oncology, nutrition, and psychosocial support services.
• Track symptom burden, nutrition status, and functional decline while diagnostic and treatment planning proceeds.
• Provide clear return precautions for bleeding, persistent vomiting, dysphagia progression, and weight-loss acceleration.
• Prepare and monitor for surgery as a primary treatment approach, with procedure pathways that may include total/partial gastrectomy, esophagogastrectomy, lymph-node dissection, gastrojejunostomy, and enteral-access tube placement.
• Support systemic therapy planning and tolerance monitoring (chemotherapy, chemoradiation, immunotherapy, and targeted therapy) after or alongside surgical management.

Pharmacology

Drug Class	Role in Care	Key Nursing Considerations
Cause-directed oncologic therapy	Systemic regimen selected after staging/subtyping	Monitor toxicity trends, functional tolerance, and adherence barriers during treatment cycles.
Supportive symptom therapy	Antiemetic, acid-suppression, pain-management pathways	Align symptom control with nutrition protection and rapid escalation for worsening bleeding/obstruction cues.

Clinical Judgment Application

Clinical Scenario

A high-risk patient with chronic H. pylori history and tobacco use reports persistent upper-abdominal discomfort and progressive food intolerance.

• Recognize Cues: High-risk history with persistent symptom progression.
• Analyze Cues: Pattern raises concern for upper-GI malignancy rather than isolated reflux.
• Prioritize Hypotheses: Immediate priority is expedited diagnostic evaluation and staging pathway activation.
• Generate Solutions: Coordinate rapid specialist referral, risk-focused education, and supportive symptom management.
• Take Action: Escalate findings to provider and initiate close follow-up for diagnostic completion.
• Evaluate Outcomes: Time to diagnostic clarification decreases and symptom burden is tracked with structured follow-up.

Related Concepts

• gastritis - Chronic gastric inflammation and H. pylori burden are important risk contributors.
• peptic-ulcer-disease-gastric-and-duodenal-ulceration - Overlapping upper-GI symptom presentations requiring differential assessment.
• abdominal-organ-enlargement-and-vascular-red-flags - Gastric-mass risk cluster context in abdominal assessment.
• proton-pump-inhibitors - Commonly co-used for acid symptom control in upper-GI care pathways.